Technology

Technology

Phage Display Antibody Library Technology
and Isolation Technology

1. Technology and knowledge on variable region amplification and optimal combinations of heavy and light chains

High-quality libraries (MOURA libraries) consisting of diverse and functional clones (>1010 size) which enable production of 100% species-specific antibodies were constructed by original gene amplification technology and knowledge.

Variable region amplification & optimal combination of heavy and light chains
2. Covering almost all antibody repertoires of individuals

Covers a wide repertoire of antibodies including autoantibodies, using B- cell fraction including pre-B cells from bone marrow and spleen.

Covering almost all antibody repertoires of individuals
3. Efficient phage antibody isolation technology-IMPACT method

Our ideas and proprietary technologies have enabled efficient screening and isolation of specific and functional phage antibodies against cell transmembrane antigens.

Phage antibody isolation technology

MabGenesis Antibody Library: MOURA* Library

Animal Health

Canine Antibodies: cMOURA Library

Quality canine phage display antibody library with diversity (>1010 size) and functionality made using B cell fraction including pre-B cells from bone marrow and spleen. cMOURA library allows for efficient discovery of 100% fully canine antibodies of interest

Feline Antibodies: fMOURA Library

Quality feline phage display antibody library with diversity (>1010 size) and functionality made using B cell fraction including pre-B cells from bone marrow and spleen. fMOURA library allows for efficient discovery of 100% fully feline antibodies of interest

Camel Antibodies: cVHH MOURA Library

Single domain antibody library with the world’s largest diversity (>1011 size) and functionality. Applicable to animal health due to low immunogenicity and stability

Human Health

Human Antibodies: hMOURA Library

A high-quality phage display antibody library with functionality and completeness covering the entire antibody gene of 1011 repertoires

Cancer cell-specific subset antibody library

hMOURA subset libraries (<106 size) after narrowing down against cell-surface antigens on 50 kinds of cancer cells. Enables efficient isolation of desired mAbs.

Camel Antibodies: cVHH MOURA Library

Single domain antibody library with the world’s largest diversity (1011 size), functionality and completeness

*"MOURA" means "comprehensiveness" in Japanese.

MabGenesis Antibody Technology Achievements

Antitumor Activity Superior to Commercially Available Antibodies
EGF Receptor

In tumor-bearing mice, it showed a stronger tumor growth inhibitory effect than Cetuximab. 1

High Affinity
TfR1

Anti-TfR antibody that currently has the strongest anti-cancer effect in the world (preparing to start human trials at other companies) 2, 3

Complex Recognition
Integrin A6B4

World’s first anti-ITG A6B4 complex antibody 4

Antibodies for low antigenic molecules
CADM1/IgSF4

World’s first anti-CADM1 / IgSF4 human antibody 5, 6, 7

Integrin A6B4 Project Antibody Evaluation

Co-administration of the integrin antibody enhances the effect of the anticancer drug and almost eliminates the tumor.

Control
Control
Control
AraC
Control
AraC + Integrin Antibody
  1. Kurosawa, G. et al. A variety of human monoclonal antibodies against epidermal growth factor receptor isolated from a phage antibody library. Biochem Biophys Res Commun 480: 94–100 (2016).
  2. US 9598496 B2
  3. Shimosaki, S. et al. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochem Biophys Res Commun 485: 144–151 (2017).
  4. WO 2015034052 A1
  5. Japanese Published Unexamined Application No. 2015-7030
  6. Nakahata, S. et al. Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia 26: 1238-1246 (2012).
  7. Chilmi, S. et al. Development of anti human CADM1 monoclonal antibodies as a potential therapy for adult T cell leukemia/lymphoma. Int J Hematol doi.org/10.1007/s12185-020-02939-126 (2020).

*These antibodies were acquired by academic efforts by Drs. Morishita and Kurosawa using our technologies before MabGenesis was founded.